Almac Group Ltd - Company Profile
Powered by 
All the data and insights you need on Almac Group Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Almac Group Ltd Strategy Report
- Understand Almac Group Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Almac Group Ltd (Almac) is a contract development and manufacturing organization. The company provides integrated services to pharmaceutical and biotechnology companies. The company offers a comprehensive range of services across the lifecycle of biopharmaceutical products which extend from research through pharmaceutical and clinical development to the commercialization of products. Its services portfolio encompasses diagnostics and biomarker development, clinical technologies, Active Pharmaceutical Ingredient (API) services and chemical development, pharmaceutical development, analytical services, clinical services and commercial services. The company operates through its subsidiaries in California, North Carolina, and Pennsylvania in the US and Singapore. Almac is headquartered in Craigavon, Northern Ireland, the UK.
Headquarters
United Kingdom
Address
Almac House, 20 Seagoe Industrial Estate, Craigavon, Northern Ireland, BT635QD
Website
www.almacgroup.com
Telephone
44 28 38332200
No of Employees
7,000
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$1.2B
Almac Group Ltd premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| - | - |
| Biomarker Discovery and Development: | Cancer DSA |
| Companion Diagnostic Development | Xcel |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into a partnership with Reach Out and Read at Children’s Hospital of Philadelphia to distribute 6,000 books at CHOP Primary Care. |
| 2023 | Plans/Strategy | In October, the company announced its plans to construct new manufacturing, production and diagnostic laboratory facilities at its global headquarters in Craigavon. |
| 2023 | Corporate Changes/Expansions | In August, Almac Diagnostic Services, a member of the Almac Group, has announced investment to expand its Next Generation Sequencing (NGS) capabilities for BioPharma partners, following the purchase and installation of the first Illumina NovaSeq X Plus instrument in Northern Ireland and the whole island of Ireland. |
Competitor Comparison
| Key Parameters | Almac Group Ltd | IQVIA Holdings Inc | Alexion Pharmaceuticals Inc | Incyte Corp | Codexis Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | United States of America | United States of America |
| City | Craigavon | Durham | Boston | Wilmington | Redwood City |
| State/Province | Northern Ireland | North Carolina | Massachusetts | Delaware | California |
| No. of Employees | 7,000 | 87,000 | 3,000 | 2,524 | 174 |
| Entity Type | Private | Public | Private | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alan Armstrong | Chairman; Chief Executive Officer | Executive Board | 2002 | - |
| Graeme McBurney | Chief Operating Officer | Senior Management | 2022 | - |
| Valarie Higgins | Managing Director - Almac Clinical Technologies; President - Almac Clinical Technologies | Senior Management | - | - |
| Paul Harkin, M.D. | Managing Director - Almac Diagnostics; President - Almac Diagnostics | Senior Management | - | - |
| Robert Dunlop, Ph.D. | Managing Director - Almac Clinical Services; President - Almac Clinical Services | Senior Management | 2001 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer